The research of D. Fernando Estrada, PhD, associate professor of biochemistry, has been recognized by the American Society for Pharmacology and Experimental Therapeutics (ASPET).

As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead liver-targeting gene therapy into human trials. | As other gene editing programs ...

Epirium Bio Inc. (Epirium), a clinical stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the upcoming presentation of two scientific posters ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company ...

The CBSE Class 12 Biology exam, set for March 25, 2025, demands more than memorization—it requires conceptual clarity, ...

CBSE Class 12 Biology Board Exam 2025 is around the corner! Ace your exam with these 10 last-minute expert tips, including ...

ISLAMABAD, PAKISTAN — Pakistan is a very young country, not just historically but also in terms of the age demographics of ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ: SEPN) for ...

Raymond James analyst Ryan Deschner lowered the firm’s price target on Inozyme (INZY) to $12 from $24 and keeps an Outperform rating on the ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics ...